SecBot SecBot
SECBOTREPLAY Home › Report › DYN

DYN · Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen…

Dyne Therapeutics, Inc. · 8-K filed Jul 20, 2026 at 07:35 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 20, 2026 at 07:35 ET

Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review with a PDUFA target date of January 21, 2027. The company expects a potential U.S. launch in Q1 2027 if approved, marking a significant regulatory milestone for this clinical-stage biotech.

  • FDA accepted BLA for z-rostudirsen (DYNE-251) for DMD exon 51 skipping
  • Priority Review granted with PDUFA target action date of January 21, 2027
  • Company expects potential U.S. launch in first quarter of 2027, assuming approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access